Current Editions
Parkinson’s pipeline pushes beyond dopamine
Cell therapies, α-synuclein programs and genetic targets are testing whether the field can finally bring disease modification closer to reality
Product Development
Emerging Company Profile
Yellowstone: Mining HLA class II for TCR therapies
Oxford spinout is using a 20-year AML biobank to develop TCR engagers against a largely untapped antigen class
Guest Commentary
Making regulation a catalyst, not a barrier, for U.K. life sciences — Lawrence Tallon
MHRA CEO argues in a Guest Commentary that for the U.K.’s long-term health and prosperity, regulation should help lead, rather than follow, innovation
Politics, Policy & Law
DeGette’s primary loss a blow to FDA reforms
The Colorado Democrat co-authored 21st Century Cures and built bipartisan consensus around fostering innovation and speeding drugs to patients
BioCentury ISSN 1097-7201